Physician profile
Ivan Borrello
NPI 1992761050
$336,382.68
in general payments reported to CMS, 2019-2025
35 companies · $82K in 2025
The $82K reported for 2025 was more than what 97% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $11K · 2020: $63.67 · 2021: $10K · 2022: $927 · 2023: $161K · 2024: $72K · 2025: $82K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $218K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $77K · Travel and Lodging: $11K · Food and Beverage: $8,576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $218,223.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $76,815.93 |
| Travel and Lodging | $10,801.76 |
| Food and Beverage | $8,575.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gamida Cell INC. | $182,619.00 | 2023-2024 | Omisirge |
| Genzyme Corporation | $85,705.69 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $20,752.70 | 2025 | Lynozyfic |
| Mckesson Sourcing Services, INC. | $18,994.39 | 2024-2025 | |
| Celgene Corporation | $10,784.92 | 2019-2025 | Breyanzi |
| Astrazeneca Uk Limited | $4,800.00 | 2025 | |
| Adaptive Biotechnologies Corporation | $4,658.65 | 2021-2025 | Clonoseq |
| Astrazeneca Pharmaceuticals LP | $2,513.50 | 2021-2025 | |
| Genetix Biotherapeutics INC | $1,326.23 | 2023-2025 | Lyfgenia |
| Janssen Biotech, INC. | $901.98 | 2023-2025 | Darzalex, Tecvayli, Talvey |
| Seagen INC. | $319.64 | 2022 | |
| Genmab U.S., INC. | $316.03 | 2023-2025 | Epkinly |
| Gilead Sciences, INC. | $271.49 | 2023-2025 | Trodelvy |
| Janssen Scientific Affairs, LLC | $265.12 | 2024-2025 | Tecvayli, Talvey, Darzalex |
| Karyopharm Therapeutics INC. | $260.81 | 2020-2025 | Xpovio |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sirtex Medical INC | $208.90 | 2022-2023 | Sir-Spheres Microspheres |
| Regeneron Pharmaceuticals, INC. | $142.53 | 2023 | |
| Adc Therapeutics America, INC. | $120.66 | 2024 | |
| Tg Therapeutics, INC. | $120.30 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $119.94 | 2022-2024 | |
| Pharmacyclics LLC, An Abbvie Company | $119.71 | 2022 | |
| Pfizer INC. | $118.96 | 2024 | |
| Kite Pharma, INC. | $116.95 | 2019 | |
| Eisai INC. | $114.09 | 2023 | |
| Daiichi Sankyo INC. | $105.01 | 2022 | |
| Novartis Pharmaceuticals Corporation | $103.85 | 2022-2024 | |
| Incyte Corporation | $100.00 | 2024 | Pemazyre, Monjuvi, Jakafi |
| Legend Biotech USA INC. | $85.09 | 2025 | Carvykti |
| Pierre Fabre Pharmaceuticals, INC. | $72.05 | 2025 | Hemangeol |
| Johnson & Johnson Health Care Systems INC. | $71.41 | 2025 | Carvykti |
| Amgen INC. | $65.60 | 2023 | Kyprolis |
| E.R. Squibb & Sons, L.L.C. | $51.22 | 2020 | |
| Menarini Silicon Biosystems, INC. | $29.59 | 2023 | Cellsearch |
| Geron Corporation | $26.67 | 2025 | Rytelo |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ivan Borrello listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.